Phaseline

Targets › UL51

UL51: drug programs, companies and trials

1 program from 1 company in 22 trials: 12 Phase 2, 6 Phase 1, 3 Phase 4, 1 Phase 3; Genitourinary, Immunology, Infectious disease; next expected readout Nov 2026.

Open in Phaseline: the race on UL51, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026

Conditions

Alcohol Use Disorder (2) Head and Neck Squamous Cell Carcinoma (2) Acute Kidney Injury (1) Insomnia (1) Giant Cell Arteritis (1) Opiate Withdrawal Syndrome (1) Ketoses, Metabolic (1) Cytomegalovirus Infections (1) Alcohol Use Disorder (AUD) (1) Relapsed/Refractory Multiple Myeloma (1) Castleman Disease (1) Relapsing Polychondritis (1)

Modalities

small molecule (1)

Companies

University of Pennsylvania (1)

Related targets

CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1) CACNB2 (1) CACNB1 (1) CACNB3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.